Percutaneous coronary intervention and the no-reflow phenomenon

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 4, 2007, Pages 715-731

  van Gaal, William J ^a   Banning, Adrian P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Distal embolization; Myocardial infarction; Myocardial reperfusion; No reflow; Percutaneous coronary intervention; Rotational atherectomy; Saphenous vein graft

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENALIN; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; INOTROPIC AGENT; NICARDIPINE; NICORANDIL; NITROPRUSSIDE SODIUM; PLACEBO; VASODILATOR AGENT; VERAPAMIL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; ARTIFICIAL EMBOLISM; BLOOD CLOT LYSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; CORONARY REPERFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; EPICARDIUM; FIBRINOLYTIC THERAPY; GUIDE WIRE; HEART BLOCK; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INOTROPISM; MICROVASCULATURE; MONOTHERAPY; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PHOTOSENSITIVITY; PREDICTION; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; ROTATIONAL ATHERECTOMY; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION; THROMBECTOMY;

ADENOSINE; ANIMALS; ATHERECTOMY, CORONARY; COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY THROMBOSIS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL REVASCULARIZATION; PROSTHESES AND IMPLANTS; REGIONAL BLOOD FLOW; SAPHENOUS VEIN; THROMBECTOMY; ULTRASONOGRAPHY, INTERVENTIONAL; VASODILATOR AGENTS;

EID: 34447294521     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.4.715     Document Type: Review

References (155)

1. Kloner RA, Ganote CE, Jennings RB. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 54(6), 1496-1508 (1974).
2. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94(7), 1528-1536 (1996).
3. Califf RM, Abdelmeguid AE, Kuntz RE et al. Myonecrosis after revascularization procedures. J. Am. Coll. Cardiol. 31(2), 241-251 (1998).
4. Herrmann J, Haude M, Lerman A et al. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 103(19), 2339-2345 (2001).
5. Mehran R, Dangas G, Mintz GS et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation 101(6), 604-610 (2000).
6. Selvanayagam JB, Porto I, Channon K et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 111(8), 1027-1032 (2005).
7. Porto I, Selvanayagam JB, van Gaal WJ et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 114(7), 662-669 (2006).
8. van Gaal WJ, Choudhury RP, Porto I et al. Prediction of distal embolization during percutaneous coronary intervention in saphenous vein grafts. Am. J. Cardiol. 99(5), 603-606 (2007).
9. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am. J. Physiol. 266(4 Pt 2), H1541-H1550 (1994).
10. Gavin JB, Thomson RW, Humphrey SM, Herdson PB. Changes in vascular morphology associated with the no-reflow phenomenon in ischaemic myocardium. Virchows Arch. A Pathol. Anat. Histopathol. 399(3), 325-332 (1983).
11. Seydoux C, Goy JJ, Davies G. Platelet and neutrophil imaging techniques in the investigation of the response to thrombolytic therapy and the no-reflow phenomenon. Am. Heart J. 125(4), 1142-1147 (1993).
12. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 80(6), 1846-1861 (1989).
13. Hickey MJ, Hurley JV, Morrison WA. Temporal and spatial relationship between no-reflow phenomenon and postischemic necrosis in skeletal muscle. Am. J. Physiol. 271(4 Pt 2), H1277-H1286 (1996).
14. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am. J. Pathol. 111(1), 98-111 (1983).
15. Sheridan FM, Cole PG, Ramage D. Leukocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model. Circulation 93(10), 1784-1787 (1996).
16. Engler RL, Dahlgren MD, Morris DD, Peterson MA, Schmid-Schonbein GW. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am. J. Physiol. 251(2 Pt 2), H314-H323 (1986).
17. Aiello EA, Jabr RI, Cole WC. Arrhythmia and delayed recovery of cardiac action potential during reperfusion after ischemia. Role of oxygen radical-induced no-reflow phenomenon. Circ. Res. 77(1), 153-162 (1995).
18. Ito H, Maruyama A, Iwakura K et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93(2), 223-228 (1996).
19. Morishima I, Sone T, Mokuno S et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am. Heart J. 130(2), 239-243 (1995).
20. Morishima I, Sone T, Okumura K et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J. Am. Coll. Cardiol. 36(4), 1202-1209 (2000).
21. Gerber BL, Rochitte CE, Melin JA et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 101(23), 2734-2741 (2000).
22. Abbo KM, Dooris M, Glazier S et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am. J. Cardiol. 75(12), 778-782 (1995).
23. Lee CH, Wong HB, Tan HC et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction - insights from a 1,328 patient registry. J. Interv. Cardiol. 18(4), 261-266 (2005).
24. Piana RN, Paik GY, Moscucci M et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 89(6), 2514-2518 (1994).
25. Ito H, Tomooka T, Sakai N et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 85(5), 1699-1705 (1992).
26. Resnic FS, Wainstein M, Lee MK et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am. Heart J. 145(1), 42-46 (2003).
27. Ellis SG, Popma JJ, Buchbinder M et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 89(2), 882-892 (1994).
28. Hanna GP, Yhip P, Fujise K et al. Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no-reflow phenomenon. Catheter Cardiovasc. Interv. 48(3), 275-278 (1999).
29. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74(5), 1124-1136 (1986).
30. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84(1), 350-356 (1991).
31. Karila-Cohen D, Czitrom D, Brochet E et al. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur. Heart J. 20(23), 1724-1730 (1999).
32. Iwakura K, Ito H. Kawano S et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J. 27(5), 534-539 (2006).
33. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-rebted arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 122(4), 1322-1332 (2002).
34. Hara M, Saikawa T, Tsunematsu Y, Sakata T, Yoshimatsu H. Predicting no-reflow based on angiographic features of lesions in patients with acute myocardial infarction. J. Atheroscler. Thromb. 12(6), 315-321 (2005).
35. Napodano M. Predictors of distal embolization during direct angioplasty for acute myocardial infarction. Presented at The 16th Annual Transcatheter Cardiovascular Therapeutics. Washington DC. USA 16-21 October 2005.
36. Tanaka A, Kawarabayashi T, Nishibori Y et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105(18), 2148-2152 (2002).
37. Watanabe T, Nanto, S, Uematsu M et al. Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction: intravascular ultrasound findings. Circ. J. 67(8), 667-671 (2003).
38. Katayama T, Kubo N, Takagi Y et al. Relation of atherothrombosis burden and volume detected by intravascular ultrasound to angiographic no-reflow phenomenon during stent implantation in patients with acute myocardial infarction. Am. J. Cardiol. 97(3), 301-304 (2006).
39. Sdringola S, Assali AR, Ghani M et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc. Interv. 54(3), 318-324 (2001).
40. Kalan JM, Roberts WC. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am. Heart J. 119(5), 1164-1184 (1990).
41. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 6(6), 594-600 (1986).
42. Saltissi S, Webb-Peploe MM, Coltart DJ. Effect of variation in coronary artery anatomy on distribution of stenotic lesions. Br. Heart J. 42(2), 186-191 (1979).
43. Assali AR, Sdringola S, Moustapha A et al. Percutaneous intervention in saphenous venous grafts: in-stent restenosis lesions are safer than de novo lesions. J. Invasive Cardiol. 13(6), 446-450 (2001).
44. Ashby DT, Dangas G, Aymong EA et al. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. J. Am. Coll. Cardiol. 41(5), 749-752 (2003).
45. Webb JG, Carere RG, Virmani R et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J. Am. Coll. Cardiol. 34(2), 468-475 (1999).
46. Baim DS, Wahr D, George B et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105(11), 1285-1290 (2002).
47. Carrozza J, Joseph P, Mumma M et al. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J. Am. Coll. Cardiol. 46(9), 1677-1683 (2005).
48. Rogers C. A prospective randomized comparison of proximal and distal protection in patients with diseased saphenous vein grafts. Presented at: The 16th Annual Transcatheter Cardiovascular Therapeutics. Washington DC, USA, 16-21 October 2005.
49. Stone GW, Rogers C, Hermiller J et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutarreous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 108(5), 548-553 (2003).
50. Dixon R. SPIDER: saphenous vein protection in a distal embolic protection randomized trial. Presented at: The 16th Annual Transcatheter Cardiovascular Therapeutics. Washington DC, USA, 16-21 October 2005.
51. Popma JJ, Cox N, Hauptmann KE et al. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. Catheter Cardiovasc. Interv. 57(2), 125-134 (2002).
52. Giugliano GR, Kuntz RE, Popma JJ, Cutlip DE, Baim DS. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am. J. Cardiol. 95(2), 173-177 (2005).
53. Stone GW, Cox DA, Babb J et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J. Am. Coll. Cardiol. 42(11), 2007-2013 (2003).
54. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330(14), 956-961 (1994).
55. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336(24), 1689-1697 (1997).
56. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 349(9063), 1422-1428 (1997).
57. Topol EJ. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352(9122), 87-92 (1998).
58. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med. 339(7), 436-443 (1998).
59. Mak K-H, Challapalli R, Eisenberg MJ et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am. J. Cardiol. 80(8), 985-988 (1997).
60. Roffi M, Mukherjee D, Chew DP et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 106(24), 3063-3067 (2002).
61. Mathew V, Grill DE, Scott CG et al. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J. Am. Coll. Cardiol. 34(4), 1163-1169 (1999).
62. Karha J, Gurm HS, Rajagopal V et al. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes. Am. J. Cardiol. 98(7), 906-910 (2006).
63. Jonas M, Stone GW, Mehran R et al. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur. Heart J. 27(8), 920-928 (2006).
64. Sdringola S, Assali A, Ghani M et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc. Interv. 51(4), 394-399 (2000).
65. Michaels AD, Appleby M, Otten MH et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J. Invasive Cardiol. 14(6), 299-302 (2002).
66. Fischell TA, Subraya RG, Ashraf K, Perry B, Haller S. Pharmacologic distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. J. Invasive Cardiol. 19(2), 58-62 (2007).
67. Salloum J, Tharpe C, Vaughan D, Zhao DX. Release and elimination of soluble vasoactive factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge GuardWire distal protection device. J. Invasive Cardiol. 17(11), 575-579 (2005).
68. Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1,000 patients. Catheter Cardiovasc. Interv. 46(3), 305-311 (1999).
69. Sharma SK, Dangas G, Mehran R et al. Risk factors for the development of slow flow during rotational coronary atherectomy. Am. J. Cardiol. 80(2), 219-222 (1997).
70. Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab: ReoPro). Circulation 98(8), 742-748 (1998).
71. Safian RD, Feldman T, Muller DW et al. Coronary Angioplasty and Rotablator Atherectomy Trial (CARAT): immediate and late results of a prospective multicenter randomized trial. Catheter Cardiovasc. Interv. 53(2), 213-220 (2001).
72. Whitlow PL, Bass TA, Kipperman RM et al. Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). Am. J. Cardiol. 87(6), 699-705 (2001).
73. Cohen BM, Weber VJ, Blum RR et al. Cocktail attenuation of rotational atherectomy flow effects (CARAFE) study: pilot study. Cathet. Cardiovasc. Diagn. 63(Suppl.), 18J-24J (1996).
74. Iwasaki K, Samukawa M, Furukawa H. Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. Am. J. Cardiol. 98(10), 1354-1356 (2006).
75. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ. J. 66(12), 1119-1123 (2002).
76. Lefkovits J, Blankenship JC, Anderson KM et al. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. J. Am. Coll. Cardiol. 28(4), 849-855 (1996).
77. Koch KC, vom Dahl J, Kleinhans E et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J. Am. Coll. Cardiol. 33(4), 998-1004 (1999).
78. Cavusoglu E, Kini AS, Marmur JD, Sharma SK. Current status of rotational atherectomy. Catheter Cardiovasc. Interv. 62(4), 485-498 (2004).
79. Henriques JPS, Zijlstra F, van't Hof AWJ et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 107(16), 2115-2119 (2003).
80. Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101(2), 125-130 (2000).
81. Henriques JPS, Zijlstra F, Ottervanger JP et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur. Heart J. 23(14), 1112-1117 (2002).
82. Mehta RH, Harjai KJ, Boura J et al. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am. J. Cardiol. 92(12), 1445-1447 (2003).
83. Nakamura T, Kubo N, Seki Y et al. Effects of a distal protection device during primary stenting in patients with acute anterior myocardial infarction. Circ. J. 68(8), 763-768 (2004).
84. Yip H-K, Wu C-J, Chang H-W et al. Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction. Am. J. Cardiol. 92(11), 1331-1335 (2003).
85. Stone GW, Webb J, Cox DA et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293(9), 1063-1072 (2005).
86. Leineweber K, Bose D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J. Am. Coll. Cardiol. 47(5), 981-986 (2006).
87. Limbruno U, Michell A, De Carlo M et al. Mechanical prevention of distal embolization during primary angioplasty: safety, & feasibility, and impact on myocardial reperfusion. Circulation 108(2), 171-176 (2003).
88. Gick M, Jander N, Bestehorn H-P et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 112(10), 1462-1469 (2005).
89. Hermiller J, Cox D, Barbeau G et al. Distal filter embolic protection in AMI - the FLAME Registry. Presented at: The 16th Annual Transcatheter Cardiovascular Therapeutics. Washington DC, USA, 16-21 October 2005.
90. Cura FA, Escudero AG, Berrocal D et al. Protection of distal embolization in high-risk patients with acute ST-segment elevation myocardial infarction (PREMIAR). Am. J. Cardiol. 99(3), 357-363 (2007).
91. Koch K. Proximal aspiration in AMI introduced: the Proxis Registry. Presented at: The 16th Annual Transcatheter Cardiovascular Therapeutics. Washington DC, USA, 16-21 October 2005.
92. Kaltoft A, Bottcher M, Nielsen SS et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation 114(1), 40-47 (2006).
93. Burzotta F, Trani C, Romagnoli E et al. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J. Am. Coll. Cardiol. 46(2), 371-376 (2005).
94. De Luca L, Sardella G, Davidson CJ et al. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction. Heart 92(7), 951-957 (2006).
95. Noel B. The export study: thromboaspiration in acute ST-elevation MI improves myocardial reperfusion. Presented at: The European Paris Course on Revascularization.Paris, France, 24-27 May 2005.
96. Svilaas T, van der Horst ICC, Zijlstra F. Thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS) - study design. Am. Heart J. 151(3), 597.e591-597.e597 (2006).
97. Colombo P. Dethrombosis to enhance acute reperfusion in myocardial infarction; DEAR-MI. Presented at The European Paris Course on Revascularization. Paris, France, 16-19 May 2006.
98. Napodano M, Pasquetto G, Sacca S et al. Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol. 42(8), 1395-1402 (2003).
99. Beran G, Lang I, Schreiber W et al. Intracoronary thrombectomy with the X-Sizer catheter system improves epicardial flow and accelerates ST-segment resolution in patients with acute coronary syndrome: a prospective, randomized, controlled study. Circulation 105(20), 2355-2360 (2002).
100. Lefevre T, Garcia E, Reimers B et al. X-Sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution: results of the X-Sizer in AMI for negligible embolization and optimal ST resolution (X AMINE ST) trial. J. Am. Coll. Cardiol. 46(2), 246-252 (2005).
101. Antoniucci D, Valenti R, Migliorini A et al. Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am. J. Cardiol. 93(8), 1033-1035 (2004).
102. Arshad A. Angiojet rheolytic thrombectomy in patients undergoing primary angioplasty for acute myocardial infarction: The AIMI study. Presented at: The 15th Annual Transcatheter Cardiovascular Therapeutics. Washington DC, USA, 27 September - 1 October 2004.
103. Burzotta F, Testa L, Giannico F et al. Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int. J. Cardiol. DOI:10.1016/j.ijcard.2006.12.018 (2007) (Epub ahead of print).
104. Neumann F-J, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98(24), 2695-2701 (1998).
105. Petronio AS, Rovai D, Musumeci G et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur. Heart J. 24(1), 67-76 (2003).
106. Gibson CM, Jennings LK, Murphy SA et al. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 110(6), 679-684 (2004).
107. De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293(14), 1759-1765 (2005).
108. De Luca G, Suryapranata H, Stone GW et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J. Am. Coll. Cardiol. 47(3), 685-686 (2006).
109. Olafsson B, Forman MB, Puett DW et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76(5), 1135-1145 (1987).
110. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 85(2), 659-665 (1992).
111. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101(18), 2154-2159 (2000).
112. Assali AR, Sdringola S, Ghani M et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc. Interv. 51(1), 27-31 (2000).
113. Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol. Heart Circ. Physiol. 285(5), H1797-H1818 (2003).
114. Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. Circulation 97(7), 692-702 (1998).
115. Mahaffey KW, Puma JA, Barbagelata NA et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 34(6), 1711-1720 (1999).
116. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. 45(11), 1775-1780 (2005).
117. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur. Heart J. 27(20), 2400-2405 (2006).
118. Maurer G. Adenosine as an adjunct to reperfusion in myocardial infarction. Eur. Heart J. 27(20), 2376-2377 (2006).
119. Quintana M, Kahan T. Adenosine may not improve clinical outcomes for people with STEMI. Commentary. Evid. Based Cardiovasc. Med. 9(4), 278-279 (2005).
120. Amit G, Cafri C, Yaroslavtsev S et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am. Heart J. 152(5), 887 e889-e814 (2006).
121. Hang CL, Wang CP, Yip HK et al. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest 128(4), 2593-2598 (2005).
122. Ito H, Taniyama Y, Iwakura K et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol. 33(3), 654-660 (1999).
123. Ishii H, Ichimiya S, Kanashiro M et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 112(9), 1284-1288 (2005).
124. Ota S, Nishikawa H, Takeuchi M et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ. J. 70(9), 1099-1104 (2006).
125. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 97(24), 2463-2469 (1998).
126. Engler R. Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia. Fed. Proc. 46(7), 2407-2412 (1987).
127. Kaminski PM, Proctor KG. Attenuation of no-reflow phenomenon, neutrophil activation, and reperfusion injury in intestinal microcirculation by topical adenosine. Circ. Res. 65(2), 426-435 (1989).
128. Zhao JL, Yang YJ, Cui CJ, You SJ, Wu YJ, Gao RL. Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion. Cardiovasc. Drugs Ther. 20(3), 167-175 (2006).
129. Fischell TA, Carter AJ, Foster MT et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet. Cardiovasc. Diagn. 45(4), 360-365 (1998).
130. Kaplan BM, Benzuly KH, Kinn JW et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet. Cardiovasc. Diagn. 39(2), 113-118 (1996).
131. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J. Am. Coll. Cardiol. 37(5), 1335-1343 (2001).
132. Taniyama Y, Ito H, Iwakura K et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 30(5), 1193-1199 (1997).
133. Vijayalakshmi K, Whittaker VJ, Kunadian B et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 92(9), 1278-1284 (2006).
134. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter. Cardiovasc. Interv. 63(2), 171-176 (2004).
135. Pasceri V, Pristipino C, Pelliccia F et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am. J. Cardiol. 95(11), 1358-1361 (2005).
136. Huang RI, Patel P, Walinsky P et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Candiovasc. Interv. 68(5), 671-676 (2006).
137. Sakata Y, Kodama K, Komamura K et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am. Heart J. 133(6), 616-621 (1997).
138. Lim SY, Bae EH, Jeong MH et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ. J. 68(10), 928-932 (2004).
139. Amado LC, Kraitchman DL, Gerber BL et al. Reduction of "no-reflow" phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J. Am. Coll. Cardiol. 43(7), 1291-1298 (2004).
140. Ishihara M, Sato H, Tateishi H, Kawagoe T, Muraoka Y, Yoshimura M. Effects of intraaortic balloon pumping on coronary hemodynamics after coronary angioplasty in patients with acute myocardial infarction. Am. Heart J. 124(5), 1133-1138 (1992).
141. Takeuchi M, Nohtomi Y, Yoshitani H, Miyazaki C, Sakamoto K, Yoshikawa J. Enhanced coronary flow velocity during intra-aortic balloon pumping assessed by transthoracic Doppler echocardiography. J. Am. Coll. Cardiol. 43(3), 368-376 (2004).
142. Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc. Interv. 57(3), 305-309 (2002).
143. Granger CB, Mahaffey KW, Weaver WD et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108(10), 1184-1190 (2003).
144. Armstrong PW, Granger CB, Adams PX et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297(1), 43-51 (2007).
145. Mahaffey KW, Granger CB, Nicolau JC et al. Effect of pexelizumab,
146. Bar FW, Tzivoni D, Dirksen MT et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur. Heart J. 27(21), 2516-2523 (2006).
147. Jang I-K, Pettigrew V, Picard MH et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J. Thromb. Thrombolysis V20(3), 147-153 (2005).
148. Dixon SR, Bartorelli AL, Marcovitz PA et al. Initial experience with hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction: results of a pilot study utilizing intracoronary aqueous oxygen therapy. J. Am. Coll. Cardiol. 39(3), 387-392 (2002).
149. Spears JR, Henney C, Prcevski P et al. Aqueous oxygen hyperbaric reperfusion in a porcine model of myocardial infarction. J. Invasive Cardiol. 14(4), 160-166 (2002).
150. Bartorelli AL. Hyperoxemic perfusion for treatment of reperfusion microvascular ischemia in patients with myocardial infarction. Am. J. Cardiovasc. Drugs 3(4), 253-263 (2003).
151. O'Neill WW; on behalf of the AMIHOT Investigators. Acute myocardial infarction with hyperoxemic therapy: a prospective, randomized, mulitcenter trial. Presented at: The Annual Scientific Session of the American College of Cardiology. New Orleans, LA, USA, 7-10 March 2004.
152. Dixon SR, Whitbourn RJ, Dae MW et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J. Am. Coll. Cardiol. 40(11), 1928-1934 (2002).
153. Miki T, Liu GS, Cohen MV, Downey JM. Mild hypothermia reduces infarct size in the beating rabbit heart: a practical intervention for acute myocardial infarction? Basic Res. Cardiol. 93(5), 372-383 (1998).
154. Dixon SR. Infarct angioplasty: beyond stents and glycoprotein IIb/IIIa inhibitors. Heart 91(Suppl. 3), III2-III6 (2005).
155. Staat P, Rioufol G, Piot C et al. Postconditioning the human heart. Circulation 112(14), 2143-2148 (2005).